Clinical Trials Logo

Advanced Solid Tumor, Adult clinical trials

View clinical trials related to Advanced Solid Tumor, Adult.

Filter by:
  • None
  • Page 1

NCT ID: NCT04972110 Recruiting - Clinical trials for Advanced Solid Tumor, Adult

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

ATTACC
Start date: July 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.

NCT ID: NCT03729596 Terminated - Melanoma Clinical Trials

MGC018 With or Without MGA012 in Advanced Solid Tumors

Start date: November 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.